Design Therapeutics, Inc.
DSGN
$14.83
$0.443.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 16.39M | 14.38M | 13.43M | 14.59M | 15.74M |
| Gross Profit | -16.39M | -14.38M | -13.43M | -14.59M | -15.74M |
| SG&A Expenses | 5.79M | 5.33M | 4.74M | 4.72M | 5.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.18M | 19.71M | 18.17M | 19.31M | 21.57M |
| Operating Income | -22.18M | -19.71M | -18.17M | -19.31M | -21.57M |
| Income Before Tax | -20.17M | -17.64M | -16.00M | -17.00M | -19.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.17M | -17.64M | -16.00M | -17.00M | -19.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.17M | -17.64M | -16.00M | -17.00M | -19.08M |
| EBIT | -22.18M | -19.71M | -18.17M | -19.31M | -21.57M |
| EBITDA | -22.03M | -19.55M | -18.01M | -19.16M | -21.42M |
| EPS Basic | -0.32 | -0.29 | -0.27 | -0.30 | -0.34 |
| Normalized Basic EPS | -0.20 | -0.18 | -0.17 | -0.19 | -0.21 |
| EPS Diluted | -0.32 | -0.29 | -0.27 | -0.30 | -0.34 |
| Normalized Diluted EPS | -0.20 | -0.18 | -0.17 | -0.19 | -0.21 |
| Average Basic Shares Outstanding | 62.51M | 61.43M | 58.74M | 56.95M | 56.86M |
| Average Diluted Shares Outstanding | 62.51M | 61.43M | 58.74M | 56.95M | 56.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |